law360.com
The 30-day deadline for the Federal Trade Commission to review Merck's $10.8 billion purchase of biotechnology company Prometheus has passed without challenge, according to a filing with the U.S. Securities and Exchange Commission by Prometheus Biosciences Inc.
over 1 year ago